These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 20828379

  • 1. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.
    Karkoulis PK, Stravopodis DJ, Margaritis LH, Voutsinas GE.
    BMC Cancer; 2010 Sep 09; 10():481. PubMed ID: 20828379
    [Abstract] [Full Text] [Related]

  • 2. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
    Karkoulis PK, Stravopodis DJ, Voutsinas GE.
    Tumour Biol; 2016 May 09; 37(5):6861-73. PubMed ID: 26662567
    [Abstract] [Full Text] [Related]

  • 3. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May 09; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 4. Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines.
    Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE.
    Cancer Cell Int; 2013 Feb 08; 13(1):11. PubMed ID: 23394616
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 6. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
    He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.
    Int J Oncol; 2013 Jan 15; 42(1):35-43. PubMed ID: 23152004
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.
    Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, He B, Jablons DM.
    J Thorac Oncol; 2008 Oct 15; 3(10):1089-95. PubMed ID: 18827603
    [Abstract] [Full Text] [Related]

  • 8. [Effects of HSP90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901].
    Chen M, Xu J, Zhao J.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb 15; 33(2):271-5. PubMed ID: 23443787
    [Abstract] [Full Text] [Related]

  • 9. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 15; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A.
    Exp Hematol; 2006 Dec 15; 34(12):1670-9. PubMed ID: 17157164
    [Abstract] [Full Text] [Related]

  • 12. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells.
    Yao JQ, Liu QH, Chen X, Yang Q, Xu ZY, Hu F, Wang L, Li JM.
    J Biomed Sci; 2010 Apr 23; 17(1):30. PubMed ID: 20416086
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H.
    Int J Oncol; 2006 Nov 23; 29(5):1111-7. PubMed ID: 17016641
    [Abstract] [Full Text] [Related]

  • 15. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
    Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM.
    Cancer Res; 2010 Nov 01; 70(21):8642-50. PubMed ID: 20841485
    [Abstract] [Full Text] [Related]

  • 16. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
    Li Y, Zhang T, Schwartz SJ, Sun D.
    Nutr Cancer; 2011 Nov 01; 63(7):1151-9. PubMed ID: 21875325
    [Abstract] [Full Text] [Related]

  • 17. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X, Ban LL, Luo G, Li ZY, Li YF, Zhou YC, Wang XC, Jin CG, Ye JG, Ma DD, Xie Q, Huang YG.
    Anticancer Drugs; 2016 Jun 01; 27(5):417-26. PubMed ID: 26872308
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O.
    Mol Cancer Ther; 2007 Mar 01; 6(3):1123-32. PubMed ID: 17363505
    [Abstract] [Full Text] [Related]

  • 20. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
    Breinig M, Mayer P, Harjung A, Goeppert B, Malz M, Penzel R, Neumann O, Hartmann A, Dienemann H, Giaccone G, Schirmacher P, Kern MA, Chiosis G, Rieker RJ.
    Clin Cancer Res; 2011 Apr 15; 17(8):2237-49. PubMed ID: 21372220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.